Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement To date, mRNA-3927 has been generally well-tolerated at the doses administered, with encouraging early signs of dose-dependent pharmacology and potential clinical benefits No occurrence of dose-limiting toxicities or study discontinuations due to drug-related treatment-emergent adverse events (TEAEs) More than 280 doses of mRNA-3927 were administered. Five patients have more than a year of dosing Phase 1/2 trial advances to the dose-expansion phase CAMBRIDGE, MA / ACCESSWIRE / May 19, 2023 / Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported on interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), presented at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting.

Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting

Its bottom line didn't turn red last quarter, as many investors might have been expecting. However, that doesn't mean the company is out of the woods.

Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%

Amazon

Chewy

Amazon is a leader in two high-growth industries and should benefit from that over time. Moderna aims to capture as much as half of the respiratory vaccine market later this decade.

3 Magnificent Growth Stocks to Buy to Help Build a Millionaire Portfolio

APA Corporation

CF Industries Holdings

Devon Energy

Enphase Energy

Diamondback Energy

Marathon Oil

Targa Resources

Growth stocks in the S&P 500 are racing back. And analysts are scrambling to choose their favorites.

Growth Stocks Are Back — Analysts Like These 8 The Best

Moderna will likely take a hit to revenue this year with fewer sales of its COVID-19 vaccine. The company is profitable and has a promising pipeline based on its mRNA technology.

Ready to Buy the Dip? This Biotech Stock Is a Smart Buy

Moderna may be close to entering a new billion-dollar market. But it's a step behind GSK and Pfizer.

Could Latecomer Moderna Match Big Pharma Rivals in RSV?

Demand for Moderna's billion-dollar product is falling. But the company has laid out plans to expand beyond the coronavirus vaccine -- and bring in billions from more than one product by 2027.

Is It Too Late to Buy Moderna Stock?

Disney

NIKE

The current recovery in the stock market has been uneven. Tech is booming, financials are lagging and everything in between is a mixed bag.

Warning! 3 Stocks That Are Waving Big Red Flags

Moderna's next big moment may come at the start of 2023's fall vaccination season. The vaccine giant's infrastructure and supply chain are ready -- and it says its discussions with commercial buyers have been "positive.

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

Cal-Maine Foods

Cullen/Frost Bankers

Insteel Industries

Teradyne

Thanks to Jerome Powell and his crew at the Federal Reserve, interest rates are about five percentage points higher than they were a year ago. For stock pickers, that means that debt once again matters.

Rates Have Risen. Here Are 5 Stocks With Little Debt

Moderna doesn't look like a value stock right now. With a big potential for its COVID-19, flu, and RSV vaccines, though, it could look like a bargain in retrospect.

Is Moderna a Value Stock to Buy Right Now?

Moderna's coronavirus vaccine revenue is declining -- but it still should remain at blockbuster levels. And the company has big plans beyond the coronavirus vaccine that could bring enormous rewards by 2027.

Is Moderna Building a Respiratory Vaccine Empire?

Moderna MRNA reported earnings of 19 cents per share for the first quarter of 2023, beating the Zacks Consensus Estimate and our model estimate of a loss of $1.77 and $2.09, respectively. Earnings declined 98% in the quarter.

Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%

An unexpected profit and promising news on a deal with the EU boosted Moderna stock.

Moderna Stock Pops on Surprise Earnings Beat

Moderna, Inc. (NASDAQ:MRNA ) Q1 2023 Results Conference Call May 4, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head, Investor Relations Stephane Bancel - Chief Executive Officer Stephen Hoge - President Arpa Garay - Chief Commercial Officer Jamey Mock - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Salveen Richter - Goldman Sachs Tara Bancroft - with TD Cowen Michael Yee - Jefferies Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Ellie Merle - UBS Luca Issi - RBC Alec Stranahan - BoA Operator Good day and thank you for standing by. Welcome to Moderna's First Quarter 2023 Conference Call.

Moderna, Inc. (MRNA) Q1 2023 Earnings Call Transcript

Applied Materials

Lam Research

Marathon Petroleum

Equinor

Rio Tinto plc Sponsored

Taiwan Semiconductor Manufacturing

While most financial advisors may direct you to blue-chip stocks to buy now, the problem with this well-meaning concept is that everybody else also has the same idea. Because of their massive footprint, these high-profile companies feature transparent, predictable businesses.

7 Blue-Chip Stocks That Have Serious Potential for the Long Haul

Moderna shares rose after the biotechnology company unexpectedly reported a profit for the first quarter and reaffirmed its 2023 COVID-19 vaccine sales expectations.  The company posted earnings per share of $0.19, down from $8.58 in the same quarter a year earlier, but significantly outperforming Wall Street's expectation of a loss per share of $1.77.

Moderna gets shot in the arm from unexpected 1Q profit, COVID vaccine sales outlook

Moderna stock advanced Thursday after the company reported unexpected profit in the first quarter and beat sales expectations. The post Moderna Jumps After Unexpectedly Reporting Profit In The First Quarter appeared first on Investor's Business Daily.

Moderna Jumps After Unexpectedly Reporting Profit In The First Quarter

Moderna (MRNA) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $1.77 per share. This compares to earnings of $8.58 per share a year ago.

Moderna (MRNA) Q1 Earnings and Revenues Beat Estimates

Moderna maintained its full-year guidance of around $5 billion in revenue from its Covid vaccine, its only marketable product.

Moderna posts surprise quarterly profit despite waning demand for Covid vaccines

Moderna Inc.'s stock MRNA, -0.96% rose 1.8% premarket Thursday, after the biotech blew past estimates for first-quarter earnings, even as profit and revenue fell sharply amid dwindling demand for COVID vaccines. The biotech posted net income of $79 million, or 19 cents a share, for the quarter, down from $3.657 billion, or $8.58 a share, in the year-earlier period.

Moderna stock up premarket after posting surprise profit and revenue that crushed estimates

First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19 Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously announced COVID-19 vaccine Advanced Purchase Agreements Company preparing for potential 2024 commercial launch of its investigational RSV vaccine for older adults Company to begin Phase 3 trial this year of mRNA-4157, Moderna's individualized neoantigen therapy (INT) in combination with Keytruda®, for melanoma Company preparing for six major vaccine launches from respiratory franchise (COVID-19, RSV, Flu, and combinations), with expected annual sales of $8-15 billion by 2027 CAMBRIDGE, MA / ACCESSWIRE / May 4, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the first quarter of 2023. "We had a strong first quarter, with $1.9 billion in revenue, clearly indicating that we are on our way to deliver on the $5 billion of signed Advance Purchase Agreements for 2023.

Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates

Eli Lilly

McKesson

Demand for Moderna's COVID-19 vaccine will taper off this year, but investors remain bullish on its prospects. McKesson is a top distributor of pharmaceuticals and a key cog in the healthcare industry.

These Have Been 3 of the Best-Performing Healthcare Stocks Since 2020

After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to determine a recommended dose CAMBRIDGE, MA / ACCESSWIRE / May 3, 2023 / Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that an abstract reporting on interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA) has been accepted for presentation at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting being held May 16-20, 2023 in Los Angeles, CA. The presentation details are as follows: Title: mRNA-3927 Therapy for Propionic Acidemia: Interim Data from a Phase 1/2 StudySession: Metabolic, Storage, Endocrine, Liver, and Gastrointestinal Diseases II Date/Time: Thursday, May 18, 2023, 04:45 PM - 05:00 PM PTPresenter: Gerald S.

Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting

As the biotech reports first-quarter earnings, the focus will be on Moderna's pipeline of future vaccines and cancer treatments and whether they can fill the hole left by dwindling Covid vaccine sales..

News for Moderna Stock (MRNA)